MedTrace Logo

Levosimendan in Acute Kidney Injury Study

NCT01720030 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-09-27

No results posted yet for this study

Summary

We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients.

Conditions

Interventions

DRUG

Levosimendan

Verum therapy

DRUG

Conventional therapy

Placebo therapy to safeguard blinding

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • VieCuri Medical Centre

    lead OTHER

Principal Investigators

  • Jos Le Noble, MD PhD · VieCuri Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720030 on ClinicalTrials.gov